Table 2.
Classification of successfully sequenced SARS-CoV-2 samples of ICU patients and immunocompromised and hospitalized patients obtained from April 2022 to December 2023 by gender, vaccine doses, mean age, and days between last dose of vaccine and infection.
| ICU (n = 99) |
Immunocompromised (n = 78) |
Hospitalized (Severe COVID-19 Symptoms) (n = 588) |
||
|---|---|---|---|---|
| Sex | Male | 49 | 47 | 309 |
| Female | 50 | 31 | 279 | |
| Vaccine doses at time of infection | 0 | 16 | 3 | 54 |
| 1 | 1 | 0 | 7 | |
| 2 | 5 | 4 | 48 | |
| 3 | 52 | 47 | 377 | |
| 4 | 22 | 16 | 96 | |
| 5 | 0 | 2 | 4 | |
| Unknown | 3 | 6 | 0 | |
| Mean age (range) | 77.5 (12–99) | 70.3 (29–92) | 77.7 (0–100) | |
| Average number of days between last dose of vaccine and infection (range) |
347.0 (52–746) | 260.8 (31–729) | 313.6 (24–728) | |